Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

ISTH SSC APEX Poster: Efficacy and Safety of Betrixaban for Extended Duration Thromboprophylaxis among Acutely Ill Medical Patients

To access The New England Journal of Medicine publication on the Phase 3 APEX study of betrixaban visit: and NEJM APEX Supplement

Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
There are no past events to display.
Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.47 (1.90%)
Data as of 07/26/16 1:23 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
06/01/16Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib in... 
Printer Friendly Version
05/31/16Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37th Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif. The presentation will be webcast live and available for replay from Portola's website at in the Investor Relations section. About Portola Pharmaceuticals, Inc.  Port... 
Printer Friendly Version
05/27/16Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016-- --Webcast with APEX Study Executive Committee Members Today at 11 a.m. ET-- MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. , May 27, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) announced that the full results of its pivotal Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study were presented today for the first time in a late-breaking clinical trial... 
Printer Friendly Version
05/23/16Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
Webcast of Investor Event to Discuss Phase 3 APEX Data to be Held on Friday, May 27 SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpelli... 
Printer Friendly Version
05/05/16Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016. “During the first quarter of 2016, we continued to advance the development of our three product candidates. We reported acceptance of our ANDEXXA™ (andexanet alfa) BLA and Phase 3 topline data from the APEX trial of betrixaban, complete... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.